Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors.
- Resource Type
- Article
- Authors
- Brose, Marcia S.; Hong, David S.; Drilon, Alexander
- Source
- JCO Precision Oncology. 9/28/2023, Vol. 7, p1-3. 3p.
- Subject
- *KINASE inhibitors
*TROPOMYOSINS
*MITOGEN-activated protein kinases
- Language
- ISSN
- 2473-4284
The co-mutation landscape of the I NTRK i fusion-positive cancer must be considered, particularly in patients who received a prior TRK inhibitor. Systemic therapies, such as chemotherapy, should instead be used for patients with unconfirmed I NTRK i fusions since cancers without an activating event are unlikely to benefit from TRK inhibition as the authors have reported. We read the retrospective study by Zhou et al[1] of a real-world population of patients with neurotrophic tyrosine receptor kinase ( I NTRK i ) fusion-positive cancers treated with tropomyosin receptor kinase (TRK) inhibitors in the Veterans Health Administration (VHA) with great interest. [Extracted from the article]